In summary, our clinical data, together with our in vitro and in vivo findings, strongly suggest that gliomas are more aggressive if they have low expression of KCNB1. Moreover, KCNB1 plays an important role in the induction of autophagy via activation of the ERK signaling pathway and could serve as a useful biomarker for the prognosis of patients with gliomas. This evidence concerns the gene KCNB1 and central nervous system cancer.